TREM2 and early-onset autosomal dominant Alzheimer disease: Gene therapies promoting overexpression of Trem2 are being investigated for treatment of Alzheimer’s Disease and other neuroinflammatory disease, while Trem2 neutralizing antibodies are being studied as a potential adjuvant to immunotherapy for solid tumors (98–101).